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Summary
BACKGROUND: In 2013, a prospective registry for adults
with congenital heart disease (CHD) was established in
Switzerland, providing detailed data on disease charac-
teristics and outcomes: Swiss Adult Congenital HEart dis-
ease Registry (SACHER). Its aim is to improve the knowl-
edge base of outcomes in adults with CHD. The registry
design and baseline patient characteristics are reported.
METHODS: All patients with structural congenital heart
defects or hereditary aortopathies, followed-up at dedicat-
ed adult CHD clinics, are asked to participate in SACHER.
Data of participants are pseudonymised and collected in
an electronic, web-based, database (secuTrial®). Collect-
ed data include detailed diagnosis, type of repair proce-
dures, previous complications and adverse outcomes dur-
ing follow-up.
RESULTS: From May 2014 to December 2016, 2836 pa-
tients (54% male, mean age 34 ± 14 years), with a wide
variety of congenital heart lesions, have been enrolled into
SACHER. Most prevalent were valve lesions (25%), fol-
lowed by shunt lesions (22%), cyanotic and other com-
plex congenital heart disease (16%), diseases affecting
the right heart, i.e., tetralogy of Fallot or Ebstein anomaly
(15%), and diseases of the left ventricular outflow tract
(13%); 337 patients (12%) had concomitant congenital
syndromes. The majority had undergone previous repair
procedures (71%), 47% of those had one or more reinter-
ventions.
CONCLUSION: SACHER collects multicentre data on
adults with CHD. Its structure enables prospective data
analysis to assess detailed, lesion-specific outcomes with
the aim to finally improve long-term outcomes.
Key words: congenital heart disease, adult congenital
heart disease, registry, SACHER
Introduction
Congenital heart disease (CHD) is the most common con-
genital defect, affecting about 1 in 100 newborns [1]. With-
out treatment, most defects of moderate or great com-
plexity have a bleak prognosis [2]. With the invention of
surgical repair techniques this has changed dramatically
and CHD has become a treatable condition with survival
into adulthood now expected for the majority of affected
patients [3]. Over the last few decades, this has led to an
ever-growing novel cohort of adult survivors with CHD [4,
5]. Although surgical repair and interventions are very ef-
fective and enable most patients to live active and produc-
tive lives, these patients are by no means “cured”. The vast
majority remains at substantially increased risk for adverse
events as young and middle-aged adults and many will
have a markedly reduced life expectancy [6]. A better un-
derstanding of risk factors for adverse outcomes and mea-
sures that may prevent such adverse outcomes are urgently
needed.
Therefore, in 2013 an initiative was started by several
stakeholders in the Swiss adult CHD community to devel-
op a national Swiss Adult Congenital HEart disease Reg-
istry (SACHER). The objectives of this registry are: (1) to
define the number of adults with CHD in Switzerland fol-
lowed up at specialised centres; and (2) to prospectively
collect data on long-term outcomes. The registry will serve
as the basis of future studies and allows national and in-
ternational collaborations. We describe registry design and
structure and present baseline patient characteristics.
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Methods
Platform of SACHER
The SACHER platform is a web-based electronic database
(secuTRial®); secuTrial® is a complete web based data
management system. The required application software is
implemented on a central server at the University Hospital
Zurich and maintained by the clinical trial unit of the Uni-
versity Hospital Zurich. Access can be obtained from any
personal computer using one of the popular browsers (e.g.,
Microsoft Internet Explorer, Mozilla Firefox, Apple Sa-
fari). The secuTrial® system complies with all regulatory
requirements regarding data safety. Each participant will
be pseudonymised (depersonalised) and participants’ data
will be entered by centre representatives or by trained
study nurses.
Structure of SACHER
The registry has three different types of CRF form – a
baseline form, a visit form and an outcome form. The base-
line form includes detailed patient characteristics, sum-
marised in table 1. The primary congenital heart defect
(main diagnosis), associated congenital cardiac lesions,
palliative and repair procedures are coded according to
the International Paediatric and Congenital Cardiac Code
(IPCCC). The main diagnosis is defined as the one con-
genital cardiac lesion with the highest lesion complexity
according the Bethesda classification [7]. In patients with
more than one main diagnosis of the same complexity
(e.g., tetralogy of Fallot and atrioventricular septal defect)
the treating cardiologist decides which diagnosis is clini-
cally more relevant to the patient, thus defining the main
diagnosis. In cases in which the main diagnosis remains
contentious, the steering committee decides on a case-by-
case basis, weighing all individual patient factors. All con-
comitant congenital defects (e.g. atrial septal defect in a
patient with tetralogy of Fallot) are labelled as “secondary
diagnoses”.
The main intervention is defined as the clinically most
definite repair operation (typically intracardiac repair pro-
cedure). Each procedure following the main intervention
(surgery or percutaneous interventions) is defined as sub-
sequent intervention. Each procedure (surgery or percuta-
neous intervention) before the main intervention is defined
as palliative intervention. Interventions are coded accord-
ing to the IPCCC.
In addition, for each patient a working diagnosis is defined.
The aim of the working diagnosis is to best capture the
patient’s current characteristics in one diagnosis, which is
based on the main intervention and the type of the underly-
ing defect (i.e., the working diagnosis differs for transpo-
sition of the great arteries with an atrial switch or with an
arterial switch repair). The list of working diagnosis as de-
fined by the steering committee is listed in table 2. If a pa-
tient cannot be labelled within one of the defined working
diagnoses, the patient will be classified within the unclas-
sified CHD group.
Visit forms consist of the basic visit form (visit at the
time of enrolment) and follow-up visit forms for each sub-
sequent clinic visit. Visit forms are divided into several
sub-forms (clinical parameters, data from cardiovascular
imaging, blood test results, exercise testing, etc.) and ad-
ditional sub-forms can be added at any time. Visit sub-
forms will serve for collection of specific data required for
a more detailed analysis or for prospective studies with-
in the registry in the future. With the aim of synchro-
nisation of follow-up visits and frequency of follow-up
procedures/investigations, minimal follow-up intervals for
major CHD subgroups and standardisation of cardiovascu-
Table 1: Case reporting form for baseline characteristics.
Variable Characteristics recorded
Demographic data
Gender Male/female
Ethnic origin Caucasian
African
Asian
Hispanic
Other
Diagnosis
Working diagnosis Diagnosis group
Working diagnosis
Main diagnosis IPCC Code
Description
Additional lesions IPCC Code
Description
Syndromes Yes/no
Marfan syndrome
Down’s syndrome (trisomy 21)
Turner’s syndrome
Noonan syndrome
Williams-Beuren syndrome
22q11.2 deletion syndrome
Other
Interventions
Main intervention (intracar-
diac repair)
IPCC Code
Description
Date of main intervention
Palliative interventions (prior
to main intervention)
IPCC Code
Description
Date of palliation
Subsequent interventions
(after main intervention)
IPCC Code
Description
Date of subsequent interventions
Prior valve implantation (ex-
cept RV-PA-conduit)
Yes/no
Mechanical valve prosthesis
Bioprosthetic valve
Valve reconstruction
Date of most recent replacement
Prior RV-PA conduit Yes/no
date of most recent conduit
Prior device implantation Yes/no
Pacemaker
AICD
CRT
Date of most device implantation
Prior cardiac complications
Myocardial infarction Yes/no, date of first occurrence
Heart failure Yes/no, date of first occurrence
Stroke/TIA Yes/no, date of first occurrence
Endocarditis Yes/no, date of first occurrence
Arrhythmias Yes/no, date of first occurrence
AVNRT/AVRT Yes/no, date of first occurrence
Atrial flutter/IART Yes/no, date of first occurrence
Atrial fibrillation Yes/no, date of first occurrence
VT/VF Yes/no, date of first occurrence
AV Block >1st degree Yes/no, date of first occurrence
Pulmonary hypertension
Other (description)
AICD = automatic implantable cardioverter defibrillator; AV block = high
degree atrioventricular block; AVNRT = atrioventricular nodal re-entrant
tachycardia; AVRT = atrioventricular re-entrant tachycardia; CRT = car-
diac resynchronisation therapy; IART = intra-atrial re-entrant tachy-
cardia; RV-PA = right ventricular to pulmonary artery; TIA = transient
ischaemic attack; VF = ventricular fibrillation; VT = ventricular tachycar-
dia
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Table 2: Number of patients for each of the working diagnoses.
Type of diagnosis Number
Unrepaired valve lesion (n = 385, 14%)
Isolated aortic valve disease without aortic dilatation 185
Bicuspid aortic valve with aortic dilatation ≥4.0cm 102
Isolated mitral valve disease 37
Isolated tricuspid valve disease (not Ebstein) 14
Pulmonary valve disease (including sub- or suprapulmonary obstruction) 47
Repaired valve lesions (n = 331, 12%)
Replaced or repaired aortic valve 119
Replaced or repaired mitral valve 15
Replaced or repaired pulmonary valve 73
Replaced or repaired tricuspid valve (excluding Ebstein's repair anomaly) 7
RVOTO relief (excluding pulmonary valve disease) 4
Multiple valves repaired/replaced (excluding Ross procedure) 16
Composite graft (Bentall procedure) 11
Ross procedure 75
David procedure 11
Shunt lesions excluding Eisenmenger physiology (n = 624, 22%)
ASD II (repaired or unrepaired) 164
VSD (repaired or unrepaired)) 227
PDA (repaired or unrepaired)) 24
Sinus venosus defect (repaired or unrepaired) 36
Partial anomalous pulmonary venous drainage (repaired or unrepaired) 31
Repaired total anomalous pulmonary venous drainage 11
Partial AVSD/ASD I (repaired or unrepaired) 67
Complete AVSD (repaired or unrepaired)) 64
Complex left ventricular outflow tract lesions (n = 377, 13%)
Subvalvular aortic stenosis (repaired or unrepaired) 44
Supravalvular aortic stenosis (repaired or unrepaired) 10
Shone complex repaired 23
Coarctation of the aorta (repaired or unrepaired)) 282
Repaired interrupted aortic arch 13
Other aortic arch anomalies 5
Hereditary aortopathies (n = 93, 3%)
Marfan syndrome 62
Other aortopathies 31
Right heart lesions (n = 415, 15%)
Repaired double chambered right ventricle (repaired and unrepaired) 7
Ebstein anomaly (repaired and unrepaired) 61
Repaired tetralogy of Fallot - without conduit 186
Repaired tetralogy of Fallot - with conduit 120
Repaired tetralogy of Fallot - Absent pulmonary valve syndrome or pulmonary atresia 29
Repaired pulmonary atresia with intact ventricular septum (biventricular repair) 12
Cyanotic and other complex lesions (n = 460, 16%)
Cyanotic heart disease – all forms, no Eisenmenger physiology 27
Eisenmenger syndrome 53
Fontan procedure 78
Atrial switch operation (Mustard or Senning) 159
Arterial switch operation (Jatene) 74
Rastelli repair 15
Congenitally corrected transposition of the great arteries 45
Repaired Common arterial trunk 9
Non-CHD or unclassified CHD lesions (n = 151, 5%)
Coronary anomalies 13
Hypertrophic cardiomyopathy (including storage disease) 69
Cardiomyopathy - neuromuscular disease 11
Left ventricular non-compaction 4
Other non-congenital heart disease 21
Other congenital heart defect 33
ASD = atrial septal defect; AVSD = atrioventricular septal defect; BAV = bicuspid aortic valve; CHD = congenital heart disease; RVOTO = right ventricular outflow tract obstruction;
VSD = ventricular septal defect
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lar tests (e.g., cardiovascular magnetic resonance imaging,
cardio-pulmonary exercise testing and echocardiography)
have been proposed by the Swiss working group for adults
with CHD [8, 9].
The outcome form is intended to collect reoperations/rein-
terventions and adverse events, including hospital admis-
sions. All subsequent interventions after inclusion will be
recorded within the outcome form, but the original main
intervention within the baseline form will not be changed
once the patient is included in the registry. Types of ad-
verse events to be collected are summarised in table 3.
Contributors to SACHER
SACHER has been initiated by board members of the na-
tional working group for adults and teenagers with con-
genital heart disease (WATCH). National programmes with
a structured service for adults with CHD (regional and
Table 3: Case report form for cardiac outcomes.
Death
Death Yes/no
Date of death
Cause of death Sudden cardiac death
Heart failure death
Other cardiac death
Perioperative death
Noncardiac death
Unknown cause
Place of death Intensive care unit
Regular ward
Home
Unknown
Hospitalisation
Admission Yes/no
Date of admission
Initial stay during admission Regular ward
Intensive care unit
Type of admission Elective
Emergency
Date of discharge
State at discharge Home
Rehabilitation facility
Other acute care hospital
Death
Reason for admission Heart failure
Arrhythmia
Other cardiac complication
Elective intervention
Emergent intervention
Delivery
Noncardiac intervention
Noncardiac reason
Interventions/operations
Operation IPCCC Code
Date of operation
Intervention IPCCC Code
Date of intervention
Cardiac complications
Bleeding Date of bleeding
Type of bleeding: intracranial, gastrointestinal, pulmonary, other
Endocarditis Date of endocarditis
Type of endocarditis: native/prosthetic
Type of valve: aortic, mitral, pulmonic, tricuspid
Systemic hypertension Date of first diagnosis
Pulmonary hypertension Date of first diagnosis
Diagnosis made by: echo/invasive
Arrhythmia Date of arrhythmia
Type of arrhythmia: atrial flutter/intra-atrial re-entrant tachycardia, atrial fibrillation, other SVT, sustained VT, non-sustained
VT, high grade AV-block, sinus node dysfunction, other
Therapy: electric conversion, medication, other, unknown
Myocardial infarction Date of myocardial infarction
Type: STEMI, NSTEMI, other
Therapy: PCI, thrombolysis, medical, unknown
Stroke Date of first occurrence
Congestive heart failure Date of first occurrence
Aortic dissection Date of first occurrence
Type A, type B
Other complications Date of other cardiac complications
Description
AV = atrioventricular; NSTEMI = non-ST elevation myocardial infarction; PCI = percutaneous coronary intervention, STEMI = ST elevation myocardial infarction; SVT = supraven-
tricular tachycardia, VT = ventricular tachycardia
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supra-regional adult CHD centres) have been invited to
contribute to the registry. Staff and infrastructural require-
ments for regional and supra-regional centres for adult
CHD in Switzerland have been defined previously [8]. All
University hospitals (Basel, Bern, Geneva, Lausanne and
Zurich) and three regional adult CHD clinics (Kantonsspi-
tal Lucerne, Kantonsspital St. Gallen and Klinik im Park)
are currently enrolling patients. Since July 2016, the Uni-
versity hospital in Vienna is also participating in the reg-
istry. The registry remains open to other centres that will
evolve in the future and fulfil requirements as defined by
the working-group [8].
SACHER is conducted by a steering committee and pro-
jects partners. The steering committee includes the heads
of the adult CHD programmes of the University hospital
Zurich (M.G.), the University hospital Berne (M.S.) and
the University hospital Basel (D.T.). Project partners in-
clude representatives from each contributing centre and
their associates. The steering committee maintains and su-
pervises the registry. Projects partners are responsible for
consenting new patients, data entering and correctness of
data assurance.
See appendix 1 for a complete list of participating centres
and investigators.
Ethics
Ethics review boards of all participating centres approved
SACHER.
Study population eligible of SACHER
All patients with congenital heart defects or hereditary
connective tissue disorders associated with aortopathies
followed at one of the participating centres (either exclu-
sively or in a shared-care model with a local hospital or a
nonspecialist cardiologist) are eligible to participate.
Inclusion procedure
Patients are approached and asked for participation by their
CHD cardiologists during clinic visits or hospital admis-
sions. A patient information form is given to the patient
and written informed consent is obtained from each partic-
ipant.
Delivery of data
Each contributing centre has access to its own data and is
allowed to analyse their data. The steering committee has
access to all pseudonymised data. Proposals for data analy-
sis with specific questions can be submitted to the steering
committee. The steering committee evaluates the research
proposals for scientific validity and for competing interests
with previously launched proposals. The steering commit-
tee decides jointly whether the project will be supported.
Statistics
In this data presentation, continuous data are reported as
medians with ranges or means and standard deviations
as appropriate. Categorical data are presented as numbers
with percentages. For between-groups comparisons chi-
square test, Fisher’s exact test, Student’s t-test or Mann-
Whitney-test were used, as appropriate. Two-sided p val-
ues <0.05 were considered significant. SPSS software (ver-
sion 23.0, SPSS Inc., Chicago, Illinois) was used for data
analysis.
Results
Active participant enrolment started in May 2014. Current-
ly (as of 1 January 2017), 2836 patients (2703 patients
from Swiss centres and 133 patients from Vienna) have
been included into the registry, of whom 1560 patients
(54.9%) were male. The increase in enrolled patients over
time is illustrated in figure 1. There was a male predom-
inance in cyanotic and other complex lesions (62% male)
and valve lesions (62% male), and a female predominance
in shunt lesions (59% female). Mean age at inclusion into
the registry was 34.1 ± 14.3 years (range: 15–88 years),
71.4% of patients were younger than 40 years, and only
129 patients (4.5%) were older than 65 years. A total of
337 patients (11.9%) had CHD associated with a syn-
drome; 109 patients (3.8%) with Down’s syndrome, 23 pa-
tients (0.8%) with Turner’s syndrome; 21 patients (0.7%)
with Noonan syndrome, 18 patients (0.6%) with known
22q11-microdeletion syndrome, 15 patients (0.5%) with
Williams-Beuren syndrome, and 75 patients (2.6%) with
Marfan syndrome. A total of 76 patients (2.7%) had rare or
unclassified syndromes.
The most prevalent main diagnoses (anatomical diagnoses)
were isolated aortic valve disease, defined as bicuspid aor-
tic valve or congenital aortic stenosis (n = 446, 15.7%) fol-
lowed by aortic coarctation (n = 286, 10.1%), tetralogy of
Fallot (n = 283, 10%) and transposition of the great arteries
(n = 242, 8.5%). The majority of patients had concomitant
defects in addition to their main anatomical diagnoses (n =
1753, 62%).
The distribution of groups of working diagnoses is listed in
table 2 and illustrated in figure 2.
Table 4 illustrates how baseline characteristics differ be-
tween patients with the same anatomical diagnosis, but dif-
ferent surgical repair techniques and thus different working
diagnosis (e.g., patients with complete transposition of the
great arteries are grouped according to the type of opera-
tion, either as atrial switch patients, arterial switch patients
or patients with Rastelli-type repairs).
Prior to inclusion into SACHER, the majority of patients
had undergone intracardiac repair (2002 patients, 71%);
of these, 934 patients (47%) had one or more reinterven-
tions after the main repair. A substantial number of patients
had undergone palliative procedures prior to intracardiac
repair (519 patients, 18%). Palliative procedures were un-
common in patients with isolated valve or shunt lesions but
were common in patients with cyanotic and other complex
defects (279, 61%). Right heart lesions (58%) and cyanot-
ic and other complex lesions (43%) had more subsequent
interventions compared to valve lesions (21%) and shunt
lesions (20%), p <0.0001.
Discussion
Since May 2014, nine national regional or supraregional
adult CHD centres and the largest centre in Austria are en-
rolling patients into SACHER. Herein we report the struc-
ture of the registry and the baseline characteristics of in-
cluded participants.
Rationale for establishing a prospective registry
Historically, evidence for adverse events and its risk fac-
tors in CHD patients is derived from retrospective analysis
of patient cohorts, often followed up at single centres.
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These analyses have provided important insights into the
outcome of CHD, but the validity of these data with re-
gards to patient management is limited because of inherent
selection bias. Randomised controlled trials comparing dif-
ferent treatment strategies would be ideal, but, for several
reasons, to date only very few randomised controlled trials
in CHD have been performed, and these are mostly under-
powered and thus with limited ability to draw firm con-
clusions. Among the most important obstacles and limita-
tions regarding the conduct of randomised controlled trials
in CHD are: (1) diversity and complexity of CHD, (2) vari-
ations in disease complexity even within an individual dis-
ease entity, (3) different types and different timing of repair
techniques, and (4) limited funding. Although many CHD
patients will have a reduced life expectancy, the majori-
ty is expected to survive for many decades into adulthood.
As a consequence, studies allowing follow-up durations of
decades rather than years are important.
Given these considerations, one way to overcome many
of the limitations of retrospective data analysis and ran-
domised trials with limited follow-up periods are prospec-
tive multicentre registries such as SACHER. The aim of
Figure 1: Monthly increase of patients enrolled into SACHER.
Figure 2: Distribution of lesions groups within SACHER. CHD = congenital heart disease; LVOT = left ventricular outflow tract
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SACHER is to establish a prospective database of detailed
clinical baseline and, ultimately, long-term follow-up in-
formation. This registry will serve as the basis for future
analysis of lesion-specific outcomes and predictors of out-
comes, as well as for future interventional studies. It also
serves as a valuable database in which to identify available
number of patients with a specific defect or type of repair
who could potentially be recruited into a randomised clini-
cal trial.
Although substantial efforts were and are made to provide
specialist care to adults with CHD in Switzerland, many
CHD patients are probably not followed up in centres with
structured adult CHD services, either because they were
lost to follow-up after paediatric care or because care is
provided by regional hospital or community-based cardi-
ologists. Thus our registry cannot yet provide meaningful
data on the overall prevalence of specific congenital heart
defects in Switzerland. As previously published national
recommendations of care for adults with CHD encourage a
model of shared care between dedicated community-based
cardiologists and adult CHD centres, a more comprehen-
sive inclusion of affected patients into this registry may be
achieved over time [8]. Currently, the distribution of main
diagnoses in SACHER is comparable to other national reg-
istries of CHD, with aortic valve disease, tetralogy of Fal-
lot and coarctation of the aorta the most frequent lesions
seen in adult CHD clinics [10].
The SACHER represents predominantly patients followed
up at dedicated adult CHD centres. Although European
guidelines recommend that all adults with CHD should be
seen at least once at such a dedicated adult CHD centre
[11], there may be a selection bias of patients with more
complex disease. These patients may be overrepresented in
SACHER, whereas simple defects, such as atrial septal de-
fects, small ventricular septal defects or patients with bi-
cuspid aortic valves may be followed at non-specialist cen-
tres.
Rationale for introducing a new classification of diag-
noses
Coding of the main CHD diagnosis in patient’s baseline
characteristics follows the reported anatomical diagnosis at
birth. However, adults with CHD, particularly those with
anatomically complex lesions, usually had intracardiac re-
pair operations in childhood that completely changed
haemodynamic profiles and, possibly, the long-term bur-
den of the underlying lesion. Furthermore, for many con-
genital heart defects (e.g., complete transposition of the
great arteries) surgical strategies substantially differ as a
result of the underlying anatomic variation or progress in
surgical techniques over time. Therefore labelling adults
by their main anatomical diagnosis may be a poor reflec-
tion of their cardiac condition as adults and may give a
very imprecise appreciation of potential long-term com-
plications during adulthood. For example, patients born
with complete transposition of the great arteries may have
undergone repair in an atrial switch operation (Mustard
or Senning operation), had an arterial switch operation
(Jatene operation) or had repair by Rastelli-type operation
(in the setting of concomitant pulmonary stenosis and ven-
tricular septal defect). Very rarely, patients with complete
transposition may even survive into adulthood without sur-
gical repair and present in adulthood as unrepaired cyan-
otic defects. It is obvious that risks of adverse outcomes
and complications will differ substantially between these
patient groups and thus the anatomical diagnosis “transpo-
sition of the great arteries” does not appropriately reflect
the haemodynamic complexity of these patients.
Another illustrative example is isolated ventricular septal
defects. If large and unrestricted, patients may develop
irreversible pulmonary hypertension with Eisenmenger
physiology before entering adulthood. Eisenmenger pa-
tients are among the highest risk patients among adults
with CHD. This is in sharp contrast to patients with small
restrictive ventricular septal defects or ventricular septal
defects surgically closed in early childhood. These patients
Table 4: Stratification of baseline characteristics for transposition of the great arteries, according to working diagnosis.
All Patients
(n = 2840)
Main diagnosis: d-
TGA*
(n = 252, 8.8%)
Working diagnosis: arteri-
al switch
(n = 74, 2.6%)
Working diagnosis: atrial
switch
(n = 159, 5.6%)
Working diagnosis:
Rastelli repair
(n = 15, 0.5%)
p-value (within d-
TGA)
Male 1560 (55%) 176 (69%) 56 (76%) 108 (68%) 11 (73%) 0.5
Age, mean 34±14 35±16 21±3 34±8 27±7 <0.001
Additional lesions 1753 (62%) 130 (52%) 44 (60%) 67 (42%) 15 (100%) <0.0001
Prior cardiac surgery 2002 (72%) 251 (99.6%)
Palliative interven-
tions
519 (18%) 195 (52%) 50 (68%) 130 (82%) 212 (80%) 0.053
Subsequent interven-
tions
934 (33%) 111 (44%) 38 (51%) 55 (35%) 14 (93%) <0.0001
Prior valve implanta-
tion
440 (15%) 12 (6%) 7 (9%) 2 (1%) 5 (33%) <0.0001
mechanical 155 (6%) 3 (1%) 3 (4%) 0 0
bioprosthesis 196 (7%) 9 (4%) 4 (5%) 1 (1%) 4 (29%)
reconstruction 89 (3%) 2 (1%) 0 1 (1%) 1 (7%)
RV or LV to PA con-
duit
296 (11%) 17 (7%) 2 (3%) 0 15 (100%) <0.0001
Prior device implanta-
tion
220 (8%) 25 (10%) 1 (1%) 20 (10%) 2 (13%) <0.0001
Pacemaker 150 (5%) 19 (8%) 1 (1%) 16 (10%) 0
AICD/CRT 70 (2%) 6 (2%) 0 4 (3%) 2 (13%)
AICD = automatic implantable cardioverter defibrillator; CRT = cardiac resynchronisation therapy; d-TGA = d-transposition of the great arteries; LV = left ventricle; PA = pulmonary
artery; RV = right ventricle * Additional working diagnoses: Fontan palliation n = 3; cyanotic heart disease (unoperated) n = 1
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have a very low risk for adverse events in adulthood and
are expected to have a normal life expectancy.
These shortcomings of classification of disease complexity
according to anatomical diagnoses will be overcome with
the introduction of the “working diagnosis” in SACHER.
The intention of working diagnoses is to allow easy iden-
tification of clinically important patient groups not only by
the main underlying anatomical defect but also by whether
or not these defects have been repaired and with what type
of repair.
Potential impact of SACHER on outcome research
The number of SACHER participants is lower than other
European registries in adults with CHD because of the
small population size of Switzerland and the short collec-
tion period [10, 12]. However, given its prospective nature,
harmonisation process for follow-up protocols and close
collaboration among the participating centres, SACHER
will provide high quality data facilitating multicentre re-
search among the participating centres. The specific struc-
ture of SACHER allows new electronic case reporting
forms to be added at any time and additional data to be col-
lected prospectively. The structure of SACHER is intend-
ed to support analysis lifelong outcomes of adult CHD pa-
tients. Ideally, in the future it would also include newborns
or children with CHD. Currently, paediatric cardiologists
in Switzerland are developing a dedicated paediatric CHD
database also based on the secuTrial® platform. With the
possibility to merge the evolving paediatric database with
SACHER, this will allow assessment and research of out-
come and treatment from the newborn to the adult patient
with CHD. Future research proposals, including collabo-
ration with researchers maintaining other registries within
or outside Switzerland, will be carefully evaluated by the
steering committee of SACHER. As one of the main goals
of SACHER is to increase the knowledge base in adult
CHD, such collaborations are generally welcome.
Conclusion
SACHER, a prospective multicentre registry, was success-
fully launched in 2014 more than 2800 patients have been
enrolled as of the end of 2016. SACHER will facilitate
multicentre outcome research. Its structure enables
prospective data analysis to assess detailed, lesion-specific
outcomes with the aim to improve long-term outcomes.
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Appendix 1
Participating centres and investigators
Steering committee
Daniel Tobler, Matthias Greutmann, Markus Schwerz-
mann
Participating centers: (Switzerland) University Hospital
Basel, Inselspital Bern, University Hospital Geneva, Uni-
versity Hospital Lausanne, Kantonsspital Luzern,, Kanton-
sspital St. Gallen, Klinik im Park, Zurich, University Hos-
pital Zurich (Austria) University Hospital Vienna,
Contributors to SACHER (mentioned as “on behalf of
SACHER”):
University Hospital Basel: Daniel Tobler, Kerstin
Buetler, Lukas Notz; University Hospital Inselspital
Bern: Markus Schwerzmann, Fabienne Schwitz, Kerstin
Wustmann, Corina Thomet; University Hospital Geneva:
Judith Bouchardy, Corelie Blanche; University Hospital
Lausanne: Judith Bouchardy, Tobias Rutz; Kantonsspital
St. Gallen: Reto Engel, Dominik Stambach, Niklas Ehl;
University Hospital Zurich: Matthias Greutmann,
Francesca Bonassin, Angela Oxenius, Christine Attenhofer
Jost, Theresa Seeliger, Bruno Santos Lopes; Kantonsspi-
tal Luzern: Hans Peter Kuen, Christoph Auf der Maur;
Klinik im Park, Zürich: Christine Attenhofer Jost, Jolan-
da Vögele; University Hospital Vienna: Harald Gabriel,
Christine Groiss
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